Any Grade >/=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1
Any hemorrhage or bleeding event >= NCI CTCAE v4.0 grade 3 within 4 weeks prior to study registration
Any grade >/=3 hemorrhage or bleeding event within 4 weeks prior to initiation of study treatment
Any hemorrhage or bleeding event ? grade 3 within 4 weeks.
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 2 or higher within 6 months before first dose of study treatment any other hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher within 6 months before first dose of study treatment
Any Grade >=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1
Grade ? 3 hemorrhage or bleeding event within 28 days prior to initiation of study treatment
Grade 3 or 4 hemorrhage within the past 3 weeks
FOR ALL PHASES (Ib AND II): Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks of start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks before the start of study treatment
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks of start of study enrollment
Any hemorrhage or bleeding event ? NCI CTCAE Grade 3 within 4 weeks prior to study registration
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug
Grade 3 or higher bleeding event =< 3 months prior to randomization
Any hemorrhage / bleeding event ? CTCAE v.4.03 Grade 3 within 4 weeks before randomization
Patients who have a history or current evidence of bleeding disorder, i.e., any hemorrhage/bleeding event of CTCAE grade >= 2, =< 28 days prior to registration
Any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks prior to the start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Patients with evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks prior to registration
Any hemorrhage or bleeding event >= grade 3 within 4 weeks prior to prior to registration
Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of first-dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug
Patients with any pulmonary hemorrhage/bleeding event grade 2 or higher within 4 weeks before randomization
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of study registration
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of study registration
Any hemorrhage or bleeding event ? NCI CTCAE Grade 3 within 4 weeks prior to start of study medication.
Pulmonary hemorrhage/bleeding event > or equal to CTCAE v4 grade 2 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event > or equal to CTCAE v4 grade 3 within 4 weeks of first dose of study drug
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE grade 3 =< 4 weeks prior to randomization
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Evidence or history of tendency or predisposition to active bleeding. Any hemorrhage or bleeding event of Grade 3 or higher within 4 weeks of start of study medication;
Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug
Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 2 or higher within 4 weeks before treatment; any other hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 3 or higher within 4 weeks before treatment
Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 2 or higher within 4 weeks before randomization; any other hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 3 or higher within 4 weeks before study entry
Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 2 or higher within 4 weeks before enrollment; any other hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 3 or higher within 4 weeks before enrollment
Evidence or history of bleeding diathesis; any hemorrhage or bleeding event >= grade 4 within 4 weeks of start of FOLFIRI
CTCAE version 4.03 > grade 2 pulmonary hemorrhage or > grade 3 of other forms of bleeding within 28 days prior to enrollment.
Contraindication to antiangiogenic agents, including: \r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 4 weeks of first dose of study drug\r\n* Any other hemorrhage/bleeding event >= grade 3 within 4 weeks of first dose of study treatment\r\n* Serious non-healing wound, ulcer, or bone fracture
Any hemorrhage or bleeding event ? NCI CTCAE Grade 3 within 4 weeks prior to study registration.
Subjects who have a history of, or current evidence of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE Grade >= 2 <4 weeks before the first dose of study drug.
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
Any hemorrhage or bleeding event >= NCI CTCAE v.4.0 grade 3 within 4 weeks prior to start of study medication
Any hemorrhage or bleeding event
Have had a hemorrhage or a bleeding event >/=Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment.
Pulmonary hemorrhage/bleeding event >= CTCAE grade 2 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug
Pulmonary hemorrhage/bleeding event > CTCAE grade 2 within 4 weeks of study entry
Any other hemorrhage/bleeding event > CTCAE grade 3 within 4 weeks of study entry
Pulmonary hemorrhage of Grade ?2 within 28 days prior to first dose of study treatment
Any other hemorrhage or bleeding of Grade ?3 within 28 days prior to first dose of study treatment
Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of > Grade 2 within 4 weeks prior to the first dose of study drug
Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding event NCI-CTCAE Grade ? 3 or higher within 4 weeks of start of investigational treatment
Any hemorrhage or bleeding event >= grade 3 within 4 weeks prior to registration
Any other hemorrhage/bleeding event >= NCI-CTCAE grade 3 within 4 weeks of enrollment
Pulmonary hemorrhage/bleeding event >= CTCAE v 4.0 grade 2 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE v 43.0 grade 3 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE grade 3 within 4 weeks of first dose of study drug
Any other hemorrhage/bleeding event >= CTCAE Grade 3 within 4 weeks of first dose of study drug
Any hemorrhage or bleeding event >= NCI CTCAE grade 3 within 4 weeks prior to start of study medication
